Effective Treatment of Latent Porto-Systemic Encephalopathy with Oral Branched Chain Amino Acids

  • E. H. Egberts
  • H. Schomerus
  • W. Hamster
  • P. Jürgens


About 60% of patients with portal hypertension without clinical signs of porto-systemic encephalopathy (PSE) and with normal EEG show substantial cerebral functional impairments1,2,3,4,5


Hepatic Encephalopathy Hepatic Coma Number Connection Subjective Side Effect Chronic Hepatic Encephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Schomerus and W. Hamster, Latent portasystemic encephalopathy, Digestion 14: 5 (1976).Google Scholar
  2. 2.
    S. Rehnström, G. Simert, J. A. Hansson, G. Johnson, and J. yang, Chronic hepatic encephalopathy. A psychometrical study, Scand. J. Gastroent. 12: 305 (1977).Google Scholar
  3. 3.
    L. Rikkers, P. Jenko, D. Rudman, and D. Freides, Subclinical hepatic encephalopathy: detection, prevalence and relationship to nitrogen metabolism, Gastroenterology 75: 462 (1978).PubMedGoogle Scholar
  4. 4.
    P. Elsass, Y. Lund, and L. Ranek, Encephalopathy in patients with cirrhosis of the liver. A neuropsychological study, Scand. J. Gastroent. 13: 241 (1978).Google Scholar
  5. 5.
    H. Schomerus, W. Hamster, H. Blunck, U. Reinhard, K. Mayer, and W. Dölle, Latent portasystemic encephalopathy, Dig. Dis. Sci. 26: 622 (1981).CrossRefGoogle Scholar
  6. 6.
    J. E. Fischer and R. J. Baldessarini, False neurotransmitters and hepatic failure, Lancet II: 75 (1971).Google Scholar
  7. 7.
    E. H. Egberts, W. Hamster, and P. Jürgens, Effect of branched chain amino acids on latent portasystemic encephalopathy, in: “Metabolism and Clinical Implications of Branched Chain Amino and Ketoacids,” Walser, Williamson, eds., Elsevier North-Holland, New York, pp. 453–463 (1981).Google Scholar
  8. 8.
    S. Udenfried, “Fluorescence Assay in Biology and Medicine,”Academic Press, New York and London, pp. 252–263 (1962).Google Scholar
  9. 9.
    W. D. Denckla and H. K. Dewey, The determination of tryptophan in plasma, liver and urine, J. Lab. & Clin. Med. 69: 160 (1967).Google Scholar
  10. 10.
    J. Laidlaw and A. E. Read; The EEG in hepatic encephalopathy, Clin. Sci. 24: 109 (1963).Google Scholar
  11. 11.
    E. A. Fleishman, A factor analysis of psychomotor abilities, J. Exp. Psychol. 46: 95 (1962).Google Scholar
  12. 12.
    B. Schneider, Some problems of repeated measurements, Rome: European Symposium on Medical Statistics, (1980).Google Scholar
  13. 13.
    H. Freund, N. Yoshimura, and J. E. Fischer, Chronic hepatic encephalopathy. Long-term therapy with a branched chain amino acid-enriched elemental diet, JAMA 242: 347 (1979).PubMedCrossRefGoogle Scholar
  14. 14.
    D. Horst, N. Grace, and H. O. Conn, A double-blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) supplement in cirrhotic patients with chronic portal-systemic encephalopathy (PSE), Chicago: AASLD (1981).Google Scholar
  15. 15.
    W. Langhans, E. Holm, U. Staedt, and M. Hartmann, Diätische Anwendung verzweigtkettiger Aminosäuren bei Patienten mit Leberzirrhose, Z. Gastroenterol. 14: 495 (1981).Google Scholar
  16. 16.
    S. Erikkson and J. Wahren, Failure of oral branched-chain amino acid administration to improve chronic hepatic encephalopathy, in: “Metabolism and Clinical Implications of Branched Chain Amino and Ketoacids,” M. Walser, J. R. Williamson eds. Elsevier North-Holland, New York, pp. 481–485 (1981).Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • E. H. Egberts
    • 1
  • H. Schomerus
    • 1
  • W. Hamster
    • 2
  • P. Jürgens
    • 3
  1. 1.Dept. I Med.Univ. KlinikTübingenWest Germany
  2. 2.Neurologische PoliklinikTübingenWest Germany
  3. 3.Allgemeines KrankenhausSt. GeorgWest Germany

Personalised recommendations